Aarti Drugs Limited on Friday announced its financial results for the quarter ended June 30, 2025 (Q1 FY26), posting a significant rise in profitability supported by improved margins and healthy revenue growth.
The company’s consolidated net profit surged 62.7% year-on-year (YoY) to ₹54 crore in Q1 FY26, compared to ₹33.2 crore in the same quarter last year. This sharp improvement came on the back of better operating performance and margin expansion.
Aarti Drugs’ revenue from operations for the quarter stood at ₹590 crore, reflecting a 6.3% increase YoY over ₹555 crore in Q1 FY25. The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) also improved, rising 14% YoY to ₹74 crore from ₹65 crore last year.
The EBITDA margin expanded to 12.6% in Q1 FY26, up from 11.7% YoY, indicating improved cost efficiencies and product mix during the quarter.
Aarti Drugs attributed the robust performance to continued demand across its key product segments and its ongoing initiatives to optimise costs and enhance operational efficiency.
The management remains optimistic about sustaining growth momentum in the coming quarters as demand for its products remains strong in both domestic and international markets.
